A Randomized Controlled Trial of an Intensive Insulin Regimen in Patients With Hyperglycemic Acute Lymphoblastic Leukemia
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
INTRODUCTION Hyperglycemia during hyper-CVAD chemotherapy is associated with poor outcomes of acute lymphoblastic leukemia (ALL). PATIENTS/METHODS To examine whether an intensive insulin regimen could improve outcomes compared with conventional anti-diabetic pharmacotherapy, a randomized trial was conducted comparing glargine plus aspart versus conventional therapy (control). Between 4/2004 and 7/2008, 52 newly diagnosed ALL, Burkitt’s lymphoma, or lymphoblastic lymphoma patients on hyper-CVAD in the inpatient setting and had random serum glucose >180 mg/dL in ≥ 2 occasions during chemotherapy were enrolled. RESULTS The trial was terminated early due to futility regarding ALL clinical outcomes despite improved glycemic control. Secondary analysis revealed that molar insulin-to-C-peptide ratio (I/C) >0.175 (a surrogate measure of exogenous insulin usage) was associated with decreased overall survival, complete remission duration and progression-free survival (PFS) while metformin and/or thiazolidinedione usage were associated with increased PFS. In multivariate analyses, factors which significantly predicted short overall survival included age≥60 years (P=0.0002), I/C≥0.175 (P=0.0016) and average glucose≥180 mg/dL (P=0.0236). Factors that significantly predicted short progression-free survival included age≥60 years (P=0.0008), I/C≥0.175 (P=0.0002), high systemic risk (P=0.0173) and average glucose≥180 mg/dL (P=0.0249). I/C ≥ 0.175 was the only significant (P=0.0042) factor that predicted short complete remission duration. CONCLUSION A glargine-plus-aspart intensive insulin regimen did not improve ALL outcomes in hyperglycemic patients. Exogenous insulin may be associated with poor outcomes while metformin and thiazolidinediones may be associated with improved outcomes. These results suggest that the choice of anti-diabetic pharmacotherapy may influence ALL outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes
Umpierrez, G. E., Isaacs, S. D., Bazargan, N., You, X., Thaler, L. M., & Kitabchi, A. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8341 · Cited by 2,195
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Dowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933
Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancer
Fenner, M. H., & Elstner, E. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.557 · Cited by 88
Cited by
Gandini, S., Puntoni, M., Heckman-Stoddard, B. M., Dunn, B. K., Ford, L., DeCensi, A., & Szabo, E. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0424 · Cited by 457
Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions
Vernieri, C., Casola, S., Foiani, M., Pietrantonio, F., de Braud, F., & Longo, V. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0615 · Cited by 202
“Systemic metabolic activities: Metformin significantly reduces blood glucose, insulinemia, cholesterol, and triglycerides in hyperglycemic/diabetic subjects and in patients experiencing glucocorticoid-induced hyperglycemia (129).”
BackgroundSteroid-induced hyperglycemia: An underdiagnosed problem or clinical inertia? A narrative review
Bonaventura, A., & Montecucco, F. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.03.006 · Cited by 108
Management of steroid-induced hyperglycemia in hospitalized patients with cancer: a review
Brady, V. J., Grimes, D., Armstrong, T., & LoBiondo-Wood, G. (2014) · Oncology nursing forum · doi:10.1188/14.onf.e355-e365 · Cited by 31
“, 2012) to using basal-bolus insulin (Gosmanov et al., 2013; Vu et al., 2012).”
Background
Metadata
- Authors
- Vu, K., Busaidy, N., Cabanillas, M. E., Konopleva, M., Faderl, S., Thomas, D. A., O'Brien, S., Broglio, K., Ensor, J., Escalante, C., Andreeff, M., Kantarjian, H., Lavis, V., & Yeung, S.-C. J.
- Venue
- Clinical Lymphoma Myeloma and Leukemia
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 12
- Issue
- 5
- Pages
- 355-362
- ISSN
- 2152-2650 (ISSN-L)
- OpenAlex
- W2084139498
- Cited by
- 44
- References
- 4
- FWCI
- 4.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.